When destiny doesn't pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan

Affiliations

• ¹ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
• ² Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
• ³ School of Medicine, University of California San Francisco, San Francisco, California, USA.
• ⁴ Department of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
• ⁵ Department of Oncology, Geneva University Hospital, Geneva, Switzerland.